Jim Cramer Suggests Waiting for Clarity on ImmunityBio Before Taking a “Hard Look”

ImmunityBio, Inc. (NASDAQ:IBRX) was among Jim Cramer’s recent stock calls on Mad Money. Answering a caller’s query about the stock during the recent lightning round, Cramer said:

You know there’s a lot of dispute about what they did. And I’m going to tell you that it is not clear exactly what they did wrong, but they got in trouble… I got to see how they get out of trouble, and then we’ll take a hard look at it.

ImmunityBio, Inc. (NASDAQ:IBRX) develops therapies designed to strengthen the immune system against infectious diseases and several cancers. A caller mentioned their small position in the stock and inquired about it during the March 27 episode. The Mad Money host replied:

Okay, that is a pure spec…. I would encourage you to own it, provided you don’t own any other spec, because that company is losing a lot of money.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.